Surgical Science Sweden AB (publ): The underlying trend is in force again
long trade In readiness |
Entrance fee: 243 kr | Goal: 329 kr | Stop the loss: 192 kr | Potential: 35.39% |
The shares in Surgical Science Sweden AB (publ) show a positive technical chart pattern in the medium term. The timing to jump back on the rising trend seems good. Investors have the opportunity to buy the share and target SEK 329. |
Summary
- From a short-term investment perspective, the company presents a deteriorating fundamental situation
Strengths
- According to sales estimates from analysts surveyed by Standard & Poor’s, the company is among the best in terms of growth.
- The company’s profit prospects over the next few years are a strong asset.
- The company’s EBITDA / sales ratio is relatively high and gives high margins before depreciation and taxes.
- The company provides high margins and thus supports the business’s profitability.
- Thanks to a sound financial situation, the company has a large investment space.
- Over the past year, analysts have regularly revised up their sales forecast for the company.
- Revised sales forecasts reflect renewed optimism among analysts covering the stock.
- Analysts have a positive view of this stock. Average consensus recommends overweight or buying the stock.
- The difference between current prices and the average target price is quite important and means a significant appreciation potential for the share.
- The average price target for analysts interested in the stock has been revised sharply upwards over the past four months.
- Analysts’ opinions have improved significantly over the past four months.
- Over the past twelve months, analysts’ opinions have been sharply revised upwards.
Weaknesses
- The company’s valuation in terms of profit multiples is quite high. In fact, the company is paid 277.15 times its estimated earnings per share for the current year.
- The company’s “enterprise value to sales” ratio is among the highest in the world.
- The company appears to be highly valued given the size of its balance sheet.
- The valuation of the company is particularly high in view of the cash flows generated by its operations.
- Sales estimates for the coming financial years vary from one analyst to another. This clearly shows the lack of transparency in the company’s future operations.
- The company’s earnings releases usually do not meet expectations.
MarketScreener.com 2021
Warning: The information, charts, data, opinions or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained therein. These articles are distributed for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated is the sole responsibility of the investor, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be held liable, whether in contracts, liability for damages, under any warranty, for errors, omissions, incorrect investments or negative development of markets.
|
|
Upcoming events at SURGICAL SCIENCE SWEDEN AB (PUBL)
Development of the income statement
Sell buy |
|
Average consensus | BUY |
Number of analysts | 2 |
Latest closing price |
243.00 SEK |
Average target price |
342.50 SEK |
Spread / Average target | 40.9% |